Literature DB >> 9198176

Antithrombin: molecular basis of deficiency.

T A Bayston1, D A Lane.   

Abstract

Antithrombin is a plasma protein regulator of coagulation proteinase activity, particularly that of thrombin. Its deficiency is a risk factor for venous thromboembolism. Considerable progress has been made in understanding the organisation and function of the antithrombin gene and protein, and the molecular basis of deficiency, all of which are reviewed, but briefly, here.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9198176

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


  9 in total

1.  Inhibitory properties of the P1 Tyr variant of antithrombin.

Authors:  Likui Yang; Chandrashekhara Manithody; Shabir H Qureshi; Alireza R Rezaie
Journal:  Biochemistry       Date:  2010-03-30       Impact factor: 3.162

2.  Complete antithrombin deficiency in mice results in embryonic lethality.

Authors:  K Ishiguro; T Kojima; K Kadomatsu; Y Nakayama; A Takagi; M Suzuki; N Takeda; M Ito; K Yamamoto; T Matsushita; K Kusugami; T Muramatsu; H Saito
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

3.  Molecular basis of the clotting defect in a bleeding patient missing the Asp-185 codon in the factor X gene.

Authors:  Qiuya Lu; Likui Yang; Chandrashekhara Manithody; Xuefeng Wang; Alireza R Rezaie
Journal:  Thromb Res       Date:  2014-08-20       Impact factor: 3.944

4.  Blood coagulation and fibrinolysis in male patients with hypogonadotropic hypogonadism: plasma factor V and factor X activities increase in hypogonadotropic hypogonadism.

Authors:  C Erem; M Kocak; A Hacihasanoglu; M Yilmaz
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

5.  Mutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin.

Authors:  J-S Bae; A R Rezaie
Journal:  J Thromb Haemost       Date:  2009-03-06       Impact factor: 5.824

6.  Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.

Authors:  Cihangir Erem; Irfan Nuhoglu; Mustafa Kocak; Mustafa Yilmaz; Safiye Tuba Sipahi; Ozge Ucuncu; Halil Onder Ersoz
Journal:  Endocrine       Date:  2008-06       Impact factor: 3.633

7.  The anti-inflammatory action of Bothrops jararaca snake antithrombin on acute inflammation induced by carrageenan in mice.

Authors:  Karen de Morais-Zani; Fernanda Peixoto Barbosa Nunes; Jacilene Barbosa da Silva; Márcio José Ferreira; Kathleen Fernandes Grego; Mônica Lopes-Ferreira; Aparecida Sadae Tanaka; Anita Mitico Tanaka-Azevedo
Journal:  Inflamm Res       Date:  2013-05-12       Impact factor: 4.575

8.  Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

Authors:  C Erem; I Nuhoglu; M Yilmaz; M Kocak; A Demirel; O Ucuncu; H Onder Ersoz
Journal:  J Endocrinol Invest       Date:  2009-02       Impact factor: 4.256

9.  Identification of antithrombin-modulating genes. Role of LARGE, a gene encoding a bifunctional glycosyltransferase, in the secretion of proteins?

Authors:  María Eugenia de la Morena-Barrio; Alfonso Buil; Ana Isabel Antón; Irene Martínez-Martínez; Antonia Miñano; Ricardo Gutiérrez-Gallego; José Navarro-Fernández; Sonia Aguila; Juan Carlos Souto; Vicente Vicente; José Manuel Soria; Javier Corral
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.